MICROBIOLOGY
One of the main focuses of Confronting antimicrobial resistance 2024 to 2029, is the ‘development and implementation of diagnostics that enable the targeted use of antimicrobials and reduce unnecessary prescribing’.
6 Hatakeyama M. Structure and function of Helicobacter pylori CagA, the first- identified bacterial protein involved in human cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(4):196-219. doi:10.2183/ pjab.93.013
7 Krahn T, Buttenschoen J, D’Souza P, et al. Success of Helicobacter pylori Guideline- based Treatment of Newly Diagnosed and Previously Treated Patients During 2007-2021 in Edmonton, Alberta. J Can Assoc Gastroenterol. 2023;7(3):221-229. doi:10.1093/jcag/gwad051
8 Argueta EA, Ho JJC, Elfanagely Y, D’Agata E, Moss SF. Clinical Implication of Drug Resistance for H. pylori Management. Antibiotics (Basel). 2022;11(12):1684. doi:10.3390/ antibiotics11121684
Seegene panel is validated for use both with stool and gastric biopsy samples, providing clinicians with the flexibility to choose a non-invasive testing option.
n Workflow integration: the assay is compatible with automated platforms, such as Seegene’s STARlet, NIMBUS, AIOS and CFX96, streamlining the diagnostic process.
n Universal assay compatibility: all Seegene molecular assays are compatible with these automated platforms, allowing laboratories to efficiently process a wide range of diagnostic tests on a single system and expand their testing repertoire.
Clinical validation studies have demonstrated the panel’s high sensitivity and specificity, with some studies showing detection sensitivity and specificity rates of 100%, and up to 100% sensitivity and specificity for the resistance mutations.11,12 This makes it a highly reliable tool for managing H. pylori infections. By identifying resistance markers upfront, this assay empowers clinicians to prescribe tailored therapies, avoiding ineffective regimens and reducing the risk of resistance spread.
Advancing diagnostics to combat AMR The rising prevalence of antibiotic- resistant H. pylori underscores the urgent need for advanced diagnostics in clinical practice. Seegene’s H. pylori & ClariR panel aligns with the UK’s AMR action plan by facilitating targeted treatments and supporting antibiotic stewardship. Integrating molecular diagnostics into
routine workflows not only improves patient outcomes but also strengthens efforts to combat antimicrobial resistance on a broader scale. As the healthcare community continues to confront the AMR crisis, adopting innovative diagnostic solutions like Seegene’s panel is essential. By enabling precise, timely detection of resistance, we can take a proactive step toward preserving the efficacy of antibiotics and ensuring better care for patients with H. pylori infections.
References 1 UK Government. Confronting antimicrobial
resistance 2024 to 2029. (
GOV.co.uk, 2024)
https://www.gov.uk/government/ publications/uk-5-year-action-plan-for- antimicrobial-resistance-2024-to-2029/ confronting-antimicrobial-resistance-2024- to-2029
2 Department of Health and Social Care. £210 million to tackle deadly antimicrobial resistance. (
GOV.co.uk, 2023) https://www.
gov.uk/government/news/210-million-to- tackle-deadly-antimicrobial-resistance
3 Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429. doi:10.1053/j. gastro.2017.04.022
4 Kayali S, Manfredi M, Gaiani F, et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018;89(8-S):72-76. doi:10.23750/abm.v89i8-S.7947
5 Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113(3):321-333. doi:10.1172/JCI20925
WWW.PATHOLOGYINPRACTICE.COM MAY 2025
9 Wong V, Hayden I, Swift C, et al. Antimicrobial resistance in Helicobacter pylori – a 10-year perspective from the National Gastrointestinal Bacteria Reference Unit, UK Health Security Agency, United Kingdom. Presented at: 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID);2024 Apr 27–30; Barcelona, Spain. Abstract ID 04369
10 Liu Q, Jin X, Cheng J, Zhou H, Zhang Y, Dai Y. Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review). Mol Med Rep. 2023;27(5):104. doi:10.3892/mmr.2023.12991
11 Jehanne Q, Bénéjat L, Mégraud F, Bessède E, Lehours P. Evaluation of the Allplex H. pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies. Helicobacter. 2020;25(4):e12702. doi:10.1111/hel.12702
12 Kim I, Maeng LS, Kim JS, et al. Quantitative multiplex real-time polymerase chain reaction assay for the detection of Helicobacter pylori and clarithromycin resistance. BMC Microbiol. 2023;23(1):155. doi:10.1186/s12866-023- 02868-z. Erratum in: BMC Microbiol. 2023 Jul 15;23(1):188. doi: 10.1186/ s12866-023-02937-3.
Dr Lynden Rooms is a Molecular Product Specialist at Mast Group. He obtained his PhD from the University of Bristol, where he investigated the molecular structure of novel antibiotic targets. He went on to complete several Post-Doctoral Research Fellowships, expanding this research to develop new antimicrobials through an integrated experimental and computational approach, collaborating with international partners across academia and industry.
0151 933 7277
sales@mast-group.com
www.mast-group.com
25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
